Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product

Reuters

06-10

Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product

Sisram Medical Ltd has announced a continuing connected transaction through a Supply Framework Agreement, effective June 10, 2025, between Sisram HK and Sisram Tianjin. Under this agreement, Sisram HK will supply the Product, botulinum toxin type A for injection, known by the trademark DAXXIFY® in English, to Fosun Wanbang (Jiangsu). The product is indicated for the temporary improvement of moderate to severe glabellar lines in adult patients. This agreement reflects Sisram Medical's ongoing efforts to expand its market presence and strengthen its partnership with Fosun Wanbang, a subsidiary of Fosun Pharma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542117753"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542117753\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542117753?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542117753","market":"us","top_or_hot":-1,"title":"Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sisram Medical Ltd has announced a continuing connected transaction through a Supply Framework Agreement, effective June 10, 2025, between Sisram HK and Sisram Tianjin. Under this agreement, Sisram HK will supply the Product, botulinum toxin type A for injection, known by the trademark DAXXIFY® in English, to Fosun Wanbang (Jiangsu). The product is indicated for the temporary improvement of moderate to severe glabellar lines in adult patients. This agreement reflects Sisram Medical's ongoing efforts to expand its market presence and strengthen its partnership with Fosun Wanbang, a subsidiary of Fosun Pharma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-10 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sisram Medical Ltd has announced a continuing connected transaction through a Supply Framework Agreement, effective June 10, 2025, between Sisram HK and Sisram Tianjin. Under this agreement, Sisram HK will supply the Product, botulinum toxin type A for injection, known by the trademark DAXXIFY® in English, to Fosun Wanbang (Jiangsu). The product is indicated for the temporary improvement of moderate to severe glabellar lines in adult patients. This agreement reflects Sisram Medical's ongoing efforts to expand its market presence and strengthen its partnership with Fosun Wanbang, a subsidiary of Fosun Pharma.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL5n4fgW:1","article_id":"2542117753","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542117753","pubTimestamp":1749557597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sisram Medical Ltd has announced a continuing connected transaction through a Supply Framework Agreement, effective June 10, 2025, between Sisram HK and Sisram Tianjin. Under this agreement, Sisram HK will supply the Product, botulinum toxin type A for injection, known by the trademark DAXXIFY in English, to Fosun Wanbang . The product is indicated for the temporary improvement of moderate to severe glabellar lines in adult patients. This agreement reflects Sisram Medical's ongoing efforts to expand its market presence and strengthen its partnership with Fosun Wanbang, a subsidiary of Fosun Pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief on June ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0187":"一线龙头","BK1593":"医美概念股","BK1585":"昨日强势股","BK0060":"抗癌","01696":"复锐医疗科技","00656":"复星国际","BK1230":"工业集团企业","BK0028":"国家队","BK0239":"医药制造","BK0188":"融资融券","BK1100":"医疗保健设备","BK0183":"MSCI概念","BK0096":"民营医院","BK0012":"证金概念"},"translate_title":"Sisram Medical Ltd.宣布肉毒杆菌毒素产品新供应框架协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":0.9,"01696":0.9},"content_text":"Sisram Medical Ltd. Announces New Supply Framework Agreement for Botulinum Toxin Product\n    \n\n        Sisram Medical Ltd has announced a continuing connected transaction through a Supply Framework Agreement, effective June 10, 2025, between Sisram HK and Sisram Tianjin. Under this agreement, Sisram HK will supply the Product, botulinum toxin type A for injection, known by the trademark DAXXIFY® in English, to Fosun Wanbang (Jiangsu). The product is indicated for the temporary improvement of moderate to severe glabellar lines in adult patients. This agreement reflects Sisram Medical's ongoing efforts to expand its market presence and strengthen its partnership with Fosun Wanbang, a subsidiary of Fosun Pharma.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}